New data presented at the 2025 World Congress of Pediatric Dermatology annual meeting highlights the efficacy and safety of ...

Icotrokinra is efficacious and safe for treating moderate to severe plaque psoriasis among adolescents and adults when compared with placebo.

Last December, it secured FDA approval for the treatment of adult patients with plaque psoriasis, regardless of the severity of their symptoms, making it an option for all the estimated eight ...

A decade-long study found that obesity was associated with a significantly increased risk for biologic treatment failure in ...

Long-term extension data show Tremfya (guselkumab) significantly reduced symptoms and inhibited structural joint damage ...

Celltrion is introducing Steqeymaq (ustekinumab-stba), which is a biosimilar to Johnson & Johnson's Stelara (ustekinumab). Steqeyma is indicated for the treatment of plaque psoriasis and psoriatic ...

Late-breaking data supported the efficacy of icotrokinra, an interleukin-23 inhibitor, for plaque psoriasis. By week 24, 46% of icotrokinra-treated patients achieved IGA 0 and 40% reached PASI 100.

Adults with moderate to severe plaque psoriasis taking the novel oral drug ... said Bissonnette. Adult and adolescent participants had a mean of 25%-27% body surface area covered with plaques.

STEQEYMA is available in both subcutaneous injection and intravenous infusion and is indicated for the treatment of plaque psoriasis (PsO) and psoriatic arthritis (PsA) in adult and pediatric patients ...